JAK2V617F mutation in patients with thrombosis: To screen or not to screen?

International Journal of Laboratory Hematology

Volumn 33, Issue 2, 2011, Pages 117-124

  Xavier, S G ^a   Gadelha, T ^b   Rezende, S M ^a   Zalcberg, I R ^c   Spector, N ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Cerebral vein thrombosis; JAK2V617F mutation; Myeloproliferative neoplasms; Splanchnic vein thrombosis; Thrombosis

Indexed keywords

JANUS KINASE 2;

ARTERY THROMBOSIS; BRAIN VEIN; GENE MUTATION; GENETIC SCREENING; HUMAN; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; REVIEW; THROMBOSIS; VEIN THROMBOSIS;

CEREBRAL VEINS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; JANUS KINASE 2; MESENTERIC VEINS; MUTATION; MYELOPROLIFERATIVE DISORDERS; THROMBOSIS;

EID: 79952464162     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2010.01275.x     Document Type: Review

References (62)

1. Abel G.A., DeAngelo D.J., Connors J.M., Sholl L.M., McCaffrey R.P. & Longtine J.A. (2008) Clinical JAK2V617F mutation testing: limited utility for general hospital patients with venous and arterial thromboses in common locations. American Journal of Hematology 83, 519-520.
2. Akada H., Yan D., Zou H., Fiering S., Hutchison R.E. & Mohi M.G. (2010) Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood First Edition Paper, prepublished online March 2, 2010; DOI
3. Alvarez-Larran A., Cervantes F., Bellosillo B., Giralt M., Julia A., Hernandez-Boluda J.C., Bosch A., Hernandez-Nieto L., Clapes V., Burgaleta C., Salvador C., Arellano-Rodrigo E., Colomer D. & Besses C. (2007) Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia 21, 1218-1223.
4. Antonioli E., Guglielmelli P., Pancrazzi A., Bogani C., Verrucci M., Ponziani V., Longo G., Bosi A. & Vannucchi A.M. (2005) Clinical implications of the JAK2V617F mutation in essential thrombocythemia. Leukemia 19, 1847-1849.
5. Arellano-Rodrigo E., Alvarez-Larran A., Reverter J.C., Villamor N., Colomer D. & Cervantes F. (2006) Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 91, 169-175.
6. Barosi G., Bergamaschi G., Marchetti M., Vannucchi A.M., Guglielmelli P., Antonioli E., Massa M., Rosti V., Campanelli R., Villani L., Viarengo G., Gattoni E., Gerli G., Specchia G., Tinelli C., Rambaldi A. & Barbui T. (2007) JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 110, 4030-4036.
7. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N., Scott M.A. & Erber W.N., The Cancer Genome Project & Green A.R. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. The Lancet 365, 1054-1061.
8. Bayraktar Y., Harmanci O., Büyükasik Y., Shorbagi A.I., Sungur A.H., Boylu C.A., Gürgey A. & Balkanci F. (2008) JAK2V617F mutation in patients with portal vein thrombosis. Digestive Diseases and Sciences 53, 2778-2783.
9. Bazzan M., Tamponi G., Schinco P., Vaccarino A., Foli C., Gallone G. & Pileri A. (1999) Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia. Annals of Hematology 78, 539-543.
10. Bellucci S., Cassinat B., Bonnin N., Marzac C. & Crassard I. (2008) The V617F-JAK2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorder. Thrombosis and Haemostasis 99, 1119-1120.
11. Campbell P.J., Scott L.M., Buck G., Wheatley K., East C.L., Marsden J.T., Duffy A., Boyd E.M., Bench A.J., Scott M.A., Vassiliou G.S., Milligan D.W., Smith S.R., Erber W.N., Bareford D., Wilkins B.S., Reilly J.T., Harrison C.N. & Green A.R. (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. The Lancet 366, 1945-1953.
12. Campbell P.J., Griesshammer M., Dohner K., Dohner H., Kusec R., Hasselbach H.C., Larsen T.S., Pallisgaard N., Giraudier S., Le Bousse-Kerdilès M.C., Desterke C., Guerton B., Dupriez B., Bordessoule D., Fenaux P., Kiladjian J.J., Viallard J.F., Brière J., Harrison C.N., Green A.R. & Reilly J.T. (2006) V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 107, 2098-2100.
13. Carobbio A., Finazzi G., Guerini V., Spinelli O., Delaini F., Marchioli R., Borrelli G., Rambaldi A. & Barbui T. (2007) Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 109, 2310-2313.
14. Cheung B., Radia D., Pantelidis P., Yadegarfar G. & Harrison C. (2006) The presence of the JAK2 V617F mutation is associated with higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. British Journal of Haematology 132, 244-245.
15. Colaizzo D., Amitrano L., Iannaccone L., Vergura P., Cappucci F., Grandone E., Guardascione M.A. & Margaglione M. (2007) Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings. Journal of Medical Genetics 44, 412-416.
16. Dahabreh I.J., Zoi K., Giannouli S., Zoi C., Loukopolos D. & Voulgarelis M. (2009) Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia Leukemia Research 33, 67-73.
17. De Stefano V., Fiorini A., Rossi E., Za T., Farina G., Chiusolo P., Sica S. & Leone G. (2007) Incidence of the JAK2V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. Journal of Thrombosis and Haemostasis 5, 708-714.
18. De Stefano V., Za T., Rossi E., Vannucchi A.M., Ruggeri M., Elli E., Micò C., Tieghi A., Cacciola R.R., Santoro C., Gerli G., Vianelli N., Guglielmelli P., Pieri L., Scognamiglio F., Rodeghiero F., Pogliani E.M., Finazzi G., Gugliotta L., Marchioli R., Leone G. & Barbui T. (2008a) Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 93, 372-380.
19. De Stefano V., Rossi E., Za T., Chiusolo P. & Leone G. (2008b) The JAK2V617F mutation in patients with cerebral venous thrombosis: a rebuttal. Thrombosis and Haemostasis 99, 1121.
20. - myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 113, 5617-5623.
21. Dentali F., Squizzato A., Appio L., Brivio L. & Ageno W. (2009b) JAK2V617F mutation in patients with arterial thrombosis in the absence of overt myeloproliferative disease. Journal of Thrombosis and Haemostasis 7, 722-725.
22. Falanga A., Marchetti M., Vignoli A., Balducci D., Russo L., Guerini V. & Barbui T. (2007) V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte and plasma hemostatic and inflammatory molecules. Experimental Hematology 35, 702-711.
23. Finazzi G., Rambaldi A., Guerini V., Carobbio A. & Barbui T. (2007) Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica 92, 135-136.
24. V617F tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis. International Journal of Laboratory Hematology 30, 415-419.
25. Heller P.G., Lev P.R., Salim J.P., Kornblihtt L.I., Goette N.P., Chazarreta C.D., Glembotsky A.C., Vassalu P.S., Marta R.F. & Molinas F.C. (2006) JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status. European Journal of Haematology 27, 210-216.
26. Hexner E.O. (2007) JAK2 V617F: implications for thrombosis in myeloproliferative diseases. Current Opinion in Hematology 14, 450-454.
27. Hsiao H.H., Yang M.Y., Liu Y.C., Lee C.P., Yang W.C., Liu T.C., Chang C.S. & Lin S.F. (2007) The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia. Experimental Hematology 35, 1704-1707.
28. James C., Ugo V., Le-Couédic J.-P., Staerk J., Delhommeau F., Lacout C., Garçon L., Raslova H., Berger R., Bennaceur-Griscelli A., Villeval J.L., Constantinescu S.N., Casadevall N. & Vainchenker W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144-1148.
29. Janssen H.L.A. & Leebeek F.W.G. (2006) JAK2 mutation: the best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis? Hepatology 44, 1391-1393.
30. Kaushansky K. (2007) The chronic myeloproliferative disorders and mutation of JAK2: Dameshek's 54year old speculation comes of age. Best Practice & Research: Clinical Haematology 20, 5-12.
31. Kiladjian J.J., Cervantes F., Leebeek F.W.G., Marzac C., Cassinat B., Chevret S., Cazals-Hatem D., Plessier A., Garcia-Pagan J.-C., Murad S.D., Raffa S., Janssen H.L.A., Gardin C., Cereja S., Tonetti C., Giraudier S., Condat B., Casadevall N., Fenaux P. & Valla D.C. (2008) The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 111, 4922-4929.
32. Kittur J., Knudson R.A., Lasho T.L., Finke C.M., Gangat N., Wolanskyj A.P., Li C.-Y., Wu W., Ketterling R.P., Pardanani A. & Tefferi A. (2007) Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 109, 2279-2284.
33. Kralovics R., Passamonti F., Buser A.S., Teo S.-S., Tiedt R., Passweg J.R., Tichelli A., Cazzola M. & Skoda R.C. (2005) A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders. New England Journal of Medicine 352, 1779-1790.
34. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., Boggon T.J., Wlodarska I., Clark J.J., Moore S., Adelsperger J., Koo S., Lee J.C., Gabriel S., Mercher T., D'Andrea A., Fröhling S., Döhner K., Marynen P., Vandenberghe P., Mesa R.A., Tefferi A., Griffin J.D., Eck M.J., Sellers W.R., Meyerson M., Golub T.R., Lee S.J. & Gilliland D.G. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and agnogenic myeloid metaplasia. Cancer Cell 7, 387-397.
35. Levine R.L., Pardanani A., Tefferi A. & Gilliland D.G. (2007) Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nature Reviews Cancer 7, 673-683.
36. Marchioli R., Finazzi G., Landolfi R., Kutti J., Gisslinger H., Patrono C., Marilus R., Villegas A., Tognoni G. & Barbui T. (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. Journal of Clinical Oncology 23, 2224-2232.
37. McMahon C., Abu-Elmagd K., Bontempo F.A., Kant J.A. & Swerdlow S.H. (2007) JAK2 V617F mutation in patients with catastrophic intra-abdominal thromboses. American Journal of Clinical Pathology 127, 736-743.
38. Ohyashiki K., Aota Y., Akahane D., Gotoh A. & Ohyashiki J.H. (2007) JAK2(V617F) mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders. Leukemia 21, 1097-1099.
39. Pardanani A., Lasho T.L., Hussein K., Schwager S.M., Finke C.M., Pruthi R.K. & Tefferi A. (2008) JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients. Mayo Clinic Proceedings 83, 457-459.
40. Passamonti F., Rumi E., Pietra D., Della Porta M.G., Boveri E., Pascutto C., Vanelli L., Arcaini L., Burcheri S., Malcovati L., Lazzarino M. & Cazzola M. (2006) Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 107, 3676-3682.
41. Patel R.K., Lea N.C., Heneghan M.A., Westwood N.B., Milojkovic D., Thanigaikumar M., Yallop D., Arya R., Pagliuca A., Gäken J., Wendon J., Heaton N.D. & Mufti G.J. (2006) Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 130, 2031-2038.
42. Primignani M. & Mannucci P.M. (2008) The role of thrombophilia in splanchnic vein thrombosis. Seminars in Liver Disease 28, 293-301.
43. Primignani M., Barosi G., Bergamaschi G., Gianelli U., Fabris F., Reati R., Dell'Era A., Bucciarelli P. & Mannucci P.M. (2006) Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 44, 1528-1534.
44. Regina S., Herault O., D'Alteroche L., Binet C. & Gruel Y. (2007) JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. Journal of Thrombosis and Haemostasis 5, 859-861.
45. Remacha A.F., Estivill C., Sarda M.P., Mateo J., Souto J.C., Canals C., Nomdedéu J. & Fontcuberta J. (2007) The V617F mutation of JAK2 is very uncommon in patients with thrombosis. Haematologica 92, 285-286.
46. Rossi D., Cresta S., Destro T., Vendramin C., Bocchetta S., De Paoli L., Cerri M., Lunghi M. & Gaidano G. (2007) JAK2V617F in idiopathic venous thromboembolism occurring in the absence of inherited or acquired thrombophilia. British Journal of Haematology 138, 813-814.
47. Sène D., Elalamy I., Ancri A. & Cacoub P. (2008) JAK2V617F mutation is not associated with unexplained recurrent arterial and venous thrombosis. Thrombosis Research 122, 427-428.
48. Shide K., Shimoda H.K., Kumano T., Karube K., Kameda T., Takenaka K., Oku S., Abe H., Katayose K.S., Kubuki Y., Kusumoto K., Hasuike S., Tahara Y., Nagata K., Matsuda T., Ohshima K., Harada M. & Shimoda K. (2008) Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia 22, 87-95.
49. Smalberg J.H., De Maat M.P.M. & Leebeek F.W.G. (2008) Absence of the JAK2 V617F mutation in patients with arterial thrombosis without overt myeloproliferative disease. Journal of Thrombosis and Haemostasis 6, 1606-1607.
50. Smith C.A. & Fan G. (2008) The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms. Human Pathology 39, 795-810.
51. Tefferi A. & Vardiman J.W. (2008b) Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22, 14-22.
52. V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. British Journal of Haematology 131, 320-328.
53. Tefferi A., Lasho T.L., Huang J., Finke C., Hanson C.A., Mesa R.A., Li C.Y., Wu W., Hanson C.A. & Pardanani A. (2008a) Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, predicts inferior overall and leukemia-free survival. Leukemia 22, 756-761.
54. Tiedt R., Hao-Shen H., Sobas M.A., Looser R., Dirnhofer S., Schwaller J. & Skoda R.C. (2008) Ratio of mutant JAK2-V617F to wild-type JAK2 determines the MPD phenotypes in transgenic mice. Blood 111, 3931-3940.
55. Ugo V., Le Gal G., Lecucq L., Mottier D., Oger E. & for the EDITH Collaborative Study Group. (2008) Prevalence of the JAK2 V617F mutation is low among unselected patients with a first episode of unprovoked thromboembolism. Journal of Thrombosis and Haemostasis 6, 203-205.
56. Vannucchi A.M., Antonioli E., Guglielmelli P., Rambaldi A., Barosi G., Marchioli R., Marfisi R.M., Finazzi G., Guerini V., Fabris F., Randi M.L., De Stefano V., Caberlon S., Tafuri A., Ruggeri M., Specchia G., Liso V., Rossi E., Pogliani E., Gugliotta L., Bosi A. & Barbui T. (2007a) Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110, 840-846.
57. V617F allele burden. Leukemia 21, 1952-1959.
58. Wolanskyj A.P., Lasho T.L., Schwager S.M., McClure R.F., Wadleigh M., Lee S.J., Gilliland D.G. & Tefferi A. (2005) JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. British Journal of Haematology 131, 208-213.
59. Xavier S.G., Gadelha T., Schaffel R., Britto L., Pimenta G., Ribeiro D.D., Sabino AP., Pires V., Renault I.Z. & Spector N. (2008) Low prevalence of the JAK2V617F in patients with ischemic stroke or cerebral venous thrombosis. Blood Coagulation & Fibrinolysis 19, 468-469.
60. Xavier S.G., Gadelha T., Pimenta G., Eugenio A.M., Ribeiro D.D., Gomes F.M., Bonamino M., Zalcberg I.R. & Spector N. (2009) JAK2V617F mutation in patients with splanchnic vein thrombosis. Digestive Diseases and Sciences, prepublished online August 19, 2009; DOI
61. Xing S., Wanting T.H., Zhao W., Ma J., Wang S., Xu X., Li Q., Fu X., Xu M. & Zhao Z.J. (2008) Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 111, 5109-5117.
62. Za T., Fiorini A., Rossi E., Ciminello A., Chiusolo P. & Leone G. (2009) Prevalence of the JAK2 V617F mutation in patients with unprovoked venous thromboembolism of common sites and without overt myeloproliferative neoplasms. British Journal of Haematology 144, 965-967.